Bevacizumab has bidirectional regulatory effects on the secretion of basic fibroblast growth factor in glioma cells

Cytokine. 2020 May:129:155022. doi: 10.1016/j.cyto.2020.155022. Epub 2020 Feb 7.

Abstract

Previous studies suggest that upregulated basic fibroblast growth factor (bFGF) plays a key role in the resistance to anti-vascular endothelial growth factor (VEGF) therapy in glioma. This study reported that anti-VEGF treatment regulated bFGF secretion in a double-edged manner. That is, moderate VEGF neutralization reduced bFGF production, whereas VEGF overblocking enhanced bFGF secretion in glioma cells. Our data provide a new perspective on the treatment of glioma with anti-VEGF, and the underlying mechanism is worthy of further study.

Keywords: Basic fibroblast growth factor; Bevacizumab; Glioma; Vascular endothelial growth factor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bevacizumab / pharmacology*
  • Bodily Secretions / drug effects
  • Bodily Secretions / metabolism
  • Cell Line, Tumor
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / metabolism
  • Fibroblast Growth Factors / metabolism*
  • Glioma / metabolism*
  • Humans

Substances

  • Bevacizumab
  • Fibroblast Growth Factors